| Size | Price | |
|---|---|---|
| 100mg | ||
| 250mg | ||
| Other Sizes |
Purity: ≥98%
| Targets |
Microtubule/Tubulin (colchicine binding site)
|
|---|---|
| ln Vitro |
Bovine brain tubulin (0.4 mg) (Cytoskeleton, Denver, CO) was mixed with various concentrations (0.625-20 μM) of test compound and incubated in 120 μL of general tubulin buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, pH 6.9, and 1 mM GTP). The absorbance of wavelength at 340 nm was monitored every 60 s for 20 min by the SYNERGY 4 microplate reader (Bio-Tek Instruments, Winooski, VT). The spectrophotometer was set at 37 °C for tubulin polymerization. The IC50 value was defined as the concentration which can inhibit 50% of microtubule polymerization.
Cell Assay: Cell Culture and Cytotoxicity Assay of Melanoma. We examined the antiproliferative activity of the ATCAA and SMART analogues in one human melanoma cell line (A375) and one mouse melanoma cell line (B16-F1). We used activity on fibroblast cells as a control to determine the selectivity of these compounds against melanoma. A375 cells and B16-F1 cells were purchased from ATCC (American Type Culture Collection, Manassas, VA). Human dermal fibroblast cells were purchased from Cascade Biologics, Inc., Portland, OR. All cell lines were cultured in DMEM (Cellgro Mediatech, Inc., Herndon, VA), supplemented with 5% FBS (Cellgro Mediatech), 1% antibiotic/antimycotic mixture (Sigma-Aldrich, Inc., St. Louis, MO), and bovine insulin (5 μg/mL; Sigma-Aldrich). Cultures were maintained at 37 °C in a humidified atmosphere containing 5% CO2. Standard sulforhodamine B assay was used. Cells were exposed to a wide range of concentrations for 48 h in round-bottomed 96-well plates. Cells were fixed with 10% trichloroacetic acid and washed five times with water. After cells were air-dried overnight and stained with SRB solution, total proteins were measured at 560 nm with a plate reader. IC50 (i.e., concentration which inhibited cell growth by 50% of no treatment controls) values were obtained by nonlinear regression analysis with GraphPad Prism (GraphPad Software, San Diego,CA). SMART compounds bind potently to the colchicine binding site in tubulin, inhibit tubulin polymerization, and arrest cancer cells in the G2/M phase of the cell cycle. They equi-potently inhibit the growth of parental and MDR-overexpressing cells in vitro, indicating that they can overcome P-glycoprotein-mediated multidrug resistance. |
| ln Vivo |
In vivo anti-tumor efficacy studies in human prostate (PC-3) and melanoma (A375) cancer xenograft models demonstrated that SMART-H and SMART-F treatments resulted in %T/C values ranging from 4-30%. SMART compounds are similarly efficacious to currently FDA-approved antitubulin drugs for cancer treatment but can circumvent drug resistance.
|
| Enzyme Assay |
A competitive mass spectrometry binding assay was developed to study the tubulin binding of SMART compounds, confirming that SMART-H specifically and reversibly binds only to the colchicine-binding site, and not to vinblastine- or paclitaxel-binding sites.
|
| Cell Assay |
Antiproliferative activity was examined in A375 human melanoma and B16-F1 mouse melanoma cells using the SRB assay after 48 hours of compound exposure, with fibroblast cells used as a non-cancerous control. The compounds demonstrated potent cytotoxicity and broad-spectrum cellular activity.
|
| Animal Protocol |
In vivo anti-tumor efficacy was evaluated in human prostate (PC-3) and melanoma (A375) cancer xenograft models. SMART-H and SMART-F treatments resulted in tumor growth inhibition with %T/C values ranging from 4-30%. Treatment for 21 days at the higher dose (15 mg/kg) failed to produce any apparent neurotoxicity.
|
| References |
J Med Chem.2009 Mar 26;52(6):1701-11;J Med Chem.2011 Jul 14;54(13):4678-93.
|
| Molecular Formula |
C19H17NO4S
|
|
|---|---|---|
| Molecular Weight |
355.408
|
|
| Exact Mass |
355.087
|
|
| CAS # |
1135797-91-9
|
|
| Related CAS # |
|
|
| PubChem CID |
25227430
|
|
| Appearance |
Typically exists as solid at room temperature
|
|
| LogP |
4.2
|
|
| Hydrogen Bond Donor Count |
0
|
|
| Hydrogen Bond Acceptor Count |
6
|
|
| Rotatable Bond Count |
6
|
|
| Heavy Atom Count |
25
|
|
| Complexity |
429
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
S1C=C(C(C2C=C(C(=C(C=2)OC)OC)OC)=O)N=C1C1C=CC=CC=1
|
|
| InChi Key |
WZEMDWPKLKAUOH-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C19H17NO4S/c1-22-15-9-13(10-16(23-2)18(15)24-3)17(21)14-11-25-19(20-14)12-7-5-4-6-8-12/h4-11H,1-3H3
|
|
| Chemical Name |
(2-phenyl-1,3-thiazol-4-yl)-(3,4,5-trimethoxyphenyl)methanone
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: soluble ( 10 mM)
Water: 1 mg/mL (Insoluble) Ethanol: 1 mg/mL |
|
|---|---|---|
| Solubility (In Vivo) |
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8137 mL | 14.0683 mL | 28.1365 mL | |
| 5 mM | 0.5627 mL | 2.8137 mL | 5.6273 mL | |
| 10 mM | 0.2814 mL | 1.4068 mL | 2.8137 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Structures ofLPA, ATCAAandSMART.J Med Chem.2009 Mar 26;52(6):1701-11. th> |
|---|
Effect of8fon tubulin assembly.J Med Chem.2009 Mar 26;52(6):1701-11. td> |
SAR relationship of the SMART molecules.J Med Chem.2009 Mar 26;52(6):1701-11. td> |